Orion Corp (ORNBV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

Orion Corp (Orion) is a developer of pharmaceuticals and diagnostic tests. The company develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients (APIs) and diagnostic tests. It focuses on developing pharmaceutical products for central nervous system disorders, cancer and respiratory. Orions client base consists of healthcare service providers and professionals, such as doctors, pharmacies, veterinarians, hospitals, healthcare centers, clinics and laboratories. The company sells its products in European markets through own human pharmaceuticals sales organization; and in international markets through several collaboration partners. It operates all manufacturing plants and most of its R&D facilities in Finland. Orion is headquartered in Espoo, Finland.

Orion Corp (ORNBV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

It derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 5
List of Figures 5
Orion Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Orion Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Orion Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Orion Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Orion Corp, Medical Devices Deals, 2012 to YTD 2018 10
Orion Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Orion Corp, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Orion and Amgen Enter into Marketing Agreement 12
Orion to Partner with Wisconsin Technology Innovation Initiative 13
Immunscape Enters into Research Collaboration with Orion 14
Orion Enters into Co-Marketing Agreement with A. Menarini Industrie Farmaceutiche Riunite 15
Orion Enters into Agreement with Asahi Kasei Pharma 16
Orion Enters into Co-Development Agreement with Helsinki University 17
Orion Enters into Agreement with Bayer for Prostate Cancer Treatment 18
Jubilant Biosys Enters Into Drug Discovery Agreement With Orion 19
Orion Enters Into R&D Agreement With Gedeon Richter For Cognitive Disorders 20
Licensing Agreements 21
Aurigene and Orion Enter into Research and Option Agreement for Epigenetics Program 21
Orion Enters Into Licensing Agreement With Janssen Pharma 22
Orion Enters into License Agreement with Phyxius Pharma 23
A. Menarini Industrie Farmaceutiche Riunite Enters into Licensing Agreement with Orion 24
Orion And Hospira Extend Licensing Agreement For Precedex 25
Mylan Enters Into Licensing Agreement With Orion for Stalevo 26
Orion Enters Into Licensing Agreement With ProStrakan For Fareston 27
Debt Offering 28
Orion Announces Public Offering Of Bond Due 2019 For US$193 Million 28
Orion Corp - Key Competitors 29
Orion Corp - Key Employees 30
Orion Corp - Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 33
Financial Announcements 33
Jul 18, 2018: Orion: Half-year financial report January-June 2018 33
Feb 07, 2018: Orion Group Financial Statement Release for 2017 46
Jul 19, 2017: Orion Group Half-Year Financial Report January-June 2017 53
Apr 26, 2017: Orion Group Interim Report JanuaryMarch 2017 62
Feb 08, 2017: Orion Group Financial Statement Release for 2016 63
Corporate Communications 66
Sep 19, 2018: Changes in responsibility areas of the Orion Group executive management board 66
Feb 13, 2017: Change in Orion Group Executive Management Board as of 21 February 2017 67
Jan 27, 2017: Reijo Salonen, Senior Vice President, Pharmaceutical R&D, is CTO of the Year 2017 68
Government and Public Interest 69
Nov 01, 2018: Orion Research Foundation grants million euros for research in 2019 69
Feb 10, 2017: Orion Research Foundation grants EUR 1 million for research 71
Product News 72
12/20/2017: Alpha 2 agonizing sedative agent Pressedex Intravenous solution 200 g Pfizer applies for adaptation to children 72
06/29/2018: CHMP announces recommendations on extensions of therapeutic indication for Dexdor 73
04/05/2017: Tenax Therapeutics Announces Review of Strategic Alternatives and Business Update 74
03/19/2017: Use of levosimendan with heart-lung machine fails to improve outcomes 75
Clinical Trials 76
Sep 01, 2017: Bayer to Present Abstract on Darolutamide at ESMO 2017 Congress 76
May 16, 2017: Tenax Meets with FDA to Discuss Positive Mortality Data and Potential Levosimendan NDA Submission 77
Jan 31, 2017: Tenax Therapeutics Announces Top-Line Results From Phase 3 LEVO-CTS Trial in Cardiac Surgery 78
Other Significant Developments 79
Sep 17, 2018: Creation of novel medicines and better patient care for the future in an ecosystem 79
Jun 14, 2018: Fermions new plant operational in Hanko-nearly 100% of production is exported 80
Feb 28, 2018: Orions Statutory Co-operation Negotiations Completed 81
Jan 04, 2018: Orion to renew operating model of its laboratories 82
Appendix 83
Methodology 83
About GlobalData 83
Contact Us 83
Disclaimer 83

List Of Tables


Orion Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Orion Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Orion Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Orion Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Orion Corp, Deals By Therapy Area, 2012 to YTD 2018 9
Orion Corp, Medical Devices Deals, 2012 to YTD 2018 10
Orion Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Orion and Amgen Enter into Marketing Agreement 12
Orion to Partner with Wisconsin Technology Innovation Initiative 13
Immunscape Enters into Research Collaboration with Orion 14
Orion Enters into Co-Marketing Agreement with A. Menarini Industrie Farmaceutiche Riunite 15
Orion Enters into Agreement with Asahi Kasei Pharma 16
Orion Enters into Co-Development Agreement with Helsinki University 17
Orion Enters into Agreement with Bayer for Prostate Cancer Treatment 18
Jubilant Biosys Enters Into Drug Discovery Agreement With Orion 19
Orion Enters Into R&D Agreement With Gedeon Richter For Cognitive Disorders 20
Aurigene and Orion Enter into Research and Option Agreement for Epigenetics Program 21
Orion Enters Into Licensing Agreement With Janssen Pharma 22
Orion Enters into License Agreement with Phyxius Pharma 23
A. Menarini Industrie Farmaceutiche Riunite Enters into Licensing Agreement with Orion 24
Orion And Hospira Extend Licensing Agreement For Precedex 25
Mylan Enters Into Licensing Agreement With Orion for Stalevo 26
Orion Enters Into Licensing Agreement With ProStrakan For Fareston 27
Orion Announces Public Offering Of Bond Due 2019 For US$193 Million 28
Orion Corp, Key Competitors 29
Orion Corp, Key Employees 30
Orion Corp, Subsidiaries 31

List Of Figures


Orion Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Orion Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Orion Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Orion Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Orion Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Orion Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Orion Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Orion Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Orion Corp, Medical Devices Deals, 2012 to YTD 2018 10

Orion Corp (ORNBV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Orion Corp (Orion) is a developer of pharmaceuticals and diagnostic tests. The company develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients (APIs) and diagnostic tests. It focuses

USD 250 View Report

Orion Corp (ORNBV) - Medical Equipment - Deals and Alliances Profile

Orion Corp (Orion) is a developer of pharmaceuticals and diagnostic tests. The company develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients (APIs) and diagnostic tests. It focuses

USD 250 View Report

Orion Corp (ORNBV) - Medical Equipment - Deals and Alliances Profile

Orion Corp (Orion) is a developer of pharmaceuticals and diagnostic tests. The company develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients (APIs) and diagnostic tests. It focuses

USD 250 View Report

Orion Corp (ORNBV) - Financial and Strategic SWOT Analysis Review

Orion Corp (ORNBV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled to bring

USD 125 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available